Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday.
Open original sourceLoading market dashboard
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday.
Open original source